A trusted leader in the renal community delivering unique products to people with kidney disease.
We are a fully integrated biopharmaceutical company. Our team works to address complications of kidney disease. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat. Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science.
VAFSEO® (vadadustat)is approved for use in 34 countries. Vadadustat has not been approved by the U.S. Food & Drug Administration.
Be part of a passionate team working to protect the kidneys and to innovate for better lives
Nearly 37 million Americans
are currently affected by chronic kidney disease.
Chronic kidney disease is a serious and life-altering illness that is persistent, progressive, and irreversible.
Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2019. Available at: https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html. Accessed: September 3, 2019.
BC-0014 (v5.0) 06/23
Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142
+1 617.871.2098 phone
+1 617.871.2099 fax